CoChat

Tumor-intrinsic PIK3CA represses tumor immunogenicity in a model of pancreatic cancer

Open access
Sivaram, Nithya, McLaughlin, Patrick A., Han, Han V., Petrenko, Oleksi, Jiang, Ya-Ping, Ballou, Lisa M., Pham, Kien, Liu, Chen, van der Velden, Adrianus W.M., Lin, Richard Z. · 2019 · Journal of Clinical Investigation

The DOI matches its Crossref record; 70 of the 71 references it cites were found in a registry or an index.

Abstract

The presence of tumor-infiltrating T cells is associated with favorable patient outcomes, yet most pancreatic cancers are immunologically silent and resistant to currently available immunotherapies. Here we show using a syngeneic orthotopic implantation model of pancreatic cancer that Pik3ca regulates tumor immunogenicity. Genetic silencing of Pik3ca in KrasG12D/Trp53R172H-driven pancreatic tumors resulted in infiltration of T cells, complete tumor regression, and 100% survival of immunocompetent host mice. By contrast, Pik3ca-null tumors implanted in T cell-deficient mice progressed and killed all of the animals. Adoptive transfer of tumor antigen-experienced T cells eliminated Pik3ca-null tumors in immunodeficient mice. Loss of PIK3CA or inhibition of its effector, AKT, increased the expression of MHC Class I and CD80 on tumor cells. These changes contributed to the increased susceptibility of Pik3ca-null tumors to T cell surveillance. Our results indicate that tumor cell PIK3CA-AKT signaling limits T cell recognition and clearance of pancreatic cancer cells. Strategies that target this pathway may yield an effective immunotherapy for this cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci123540

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Proliferation of αKO pancreatic cancer cells in vitro and regression in vivo. (A) Proliferation rates of KPC cell lines in standard 2D culture. Cells plated in triplicate were counted at the times indicated (mean ± SEM; n = 3). *P = 0.0191, WT versus αKO; **P = 0.375, WT versus EgfrKO (1-way ANOVA with Bonferroni’s post hoc test). (B) Percentage of cells positive for annexin V staining at the 4-day time point in A (mean ± SEM, n = 3). P = 0.18, WT versus αKO; P = 0.12, WT versus EgfrKO (1-way ANOVA with Bonferroni’s post hoc test). (C) Representative light microscopy images (×40 magnification) of spheroids formed after 5 days in 3D methylcellulose culture. (D) Cells (0.5 million) were implanted in the head of the pancreas of B6 mice. Tumor growth was monitored by IVIS imaging of the luciferase signal on days 1, 7, and 14 after implantation. Representative images of 3 mice in each group are shown. (E) Quantification of luciferase signals from each mouse. The bars indicate median. On day 7, ***P = 0.0006, WT versus αKO and P > 0.9, WT versus EgfrKO; on day 14, ****P < 0.0001, WT versus αKO and P = 0.0618, WT versus EgfrKO (Kruskal-Wallis test with Dunn’s post hoc test). (F) Kaplan-Meier survival curves for B6 mice implanted with the indicated cell lines. Median survival: WT, 16 days (n = 16); EgfrKO, 17 days (n = 10); all αKO mice were alive at day 80 (n = 17). P < 0.0001, WT versus αKO (log-rank test). (G) H&E-stained sections of pancreatic tissue collected at the indicated times after cell implantation in B6 mice. Scale bar: 100 μm.
Figure 1 Proliferation of αKO pancreatic cancer cells in vitro and regression in vivo. (A) Proliferation rates of KPC cell lines in standard 2D culture. Cells plated in triplicate were counted at the times indicated (mean ± SEM; n = 3). *P = 0.0191, WT versus αKO; **P = 0.375, WT versus EgfrKO (1-way ANOVA with Bonferroni’s post hoc test). (B) Percentage of cells positive for annexin V staining at the 4-day time point in A (mean ± SEM, n = 3). P = 0.18, WT versus αKO; P = 0.12, WT versus EgfrKO (1-way ANOVA with Bonferroni’s post hoc test). (C) Representative light microscopy images (×40 magnification) of spheroids formed after 5 days in 3D methylcellulose culture. (D) Cells (0.5 million) were implanted in the head of the pancreas of B6 mice. Tumor growth was monitored by IVIS imaging of the luciferase signal on days 1, 7, and 14 after implantation. Representative images of 3 mice in each group are shown. (E) Quantification of luciferase signals from each mouse. The bars indicate median. On day 7, ***P = 0.0006, WT versus αKO and P > 0.9, WT versus EgfrKO; on day 14, ****P < 0.0001, WT versus αKO and P = 0.0618, WT versus EgfrKO (Kruskal-Wallis test with Dunn’s post hoc test). (F) Kaplan-Meier survival curves for B6 mice implanted with the indicated cell lines. Median survival: WT, 16 days (n = 16); EgfrKO, 17 days (n = 10); all αKO mice were alive at day 80 (n = 17). P < 0.0001, WT versus αKO (log-rank test). (G) H&E-stained sections of pancreatic tissue collected at the indicated times after cell implantation in B6 mice. Scale bar: 100 μm.CC BY · PubMed Central
Figure 2 T cell infiltration of αKO tumors and the requirement of CD4+ and CD8+ T cells for αKO tumor regression. (A and B) WT, αKO, or EgfrKO cells (0.5 million) were implanted in the head of the pancreas of B6 mice, and pancreata were harvested 10 days later (EgfrKO, n = 3; WT and αKO, n = 4). (A) Sections were stained with H&E, or IHC was performed with the indicated antibodies. Representative sections are shown. Scale bar: 100 μm. (B) Quantification of tumor-infiltrating cells positive for CD3, CD4, CD8, or F4/80. Bars indicate mean ± SEM. WT versus αKO, ***P = 0.0008, ****P = 0.0001, and *P = 0.0005 for CD3, CD4, and CD8, respectively (1-way ANOVA with Bonferroni’s post hoc test). (C–G) αKO cells (0.5 million) were implanted in the head of the pancreas of B6 mice injected with neutralizing CD4 and CD8 antibodies (αCD4/8, green) or PBS (control), or CD4KO (blue squares) or CD8KO (red diamonds) mice. (C) Quantification of luciferase signals from IVIS images of each mouse. Bars indicate median. **P < 0.005 (2-tailed Wilcoxon signed-rank test). (D) Kaplan-Meier survival curves for αCD4/8 (n = 5; median survival: 29 days), CD4KO (n = 9; median survival: 47 days), and CD8KO (n = 8; median survival: 37 days) mice implanted with αKO cells. P = 0.0017 (log-rank test, CD4KO vs CD8KO). (E) H&E-stained pancreatic sections from αCD4/8 and control mice. (F) IHC staining of pancreatic sections with antibodies against CD4 or CD8. Pancreata were collected from CD4KO or CD8KO mice at the humane endpoint. For comparison, sections of pancreata collected 10 days after implantation of B6 mice with 0.5 million αKO cells are shown. Scale bars: 100 μm. (G) Quantification of tumor-infiltrating CD4+ or CD8+ T cells from pancreatic sections.
Figure 2 T cell infiltration of αKO tumors and the requirement of CD4+ and CD8+ T cells for αKO tumor regression. (A and B) WT, αKO, or EgfrKO cells (0.5 million) were implanted in the head of the pancreas of B6 mice, and pancreata were harvested 10 days later (EgfrKO, n = 3; WT and αKO, n = 4). (A) Sections were stained with H&E, or IHC was performed with the indicated antibodies. Representative sections are shown. Scale bar: 100 μm. (B) Quantification of tumor-infiltrating cells positive for CD3, CD4, CD8, or F4/80. Bars indicate mean ± SEM. WT versus αKO, ***P = 0.0008, ****P = 0.0001, and *P = 0.0005 for CD3, CD4, and CD8, respectively (1-way ANOVA with Bonferroni’s post hoc test). (C–G) αKO cells (0.5 million) were implanted in the head of the pancreas of B6 mice injected with neutralizing CD4 and CD8 antibodies (αCD4/8, green) or PBS (control), or CD4KO (blue squares) or CD8KO (red diamonds) mice. (C) Quantification of luciferase signals from IVIS images of each mouse. Bars indicate median. **P < 0.005 (2-tailed Wilcoxon signed-rank test). (D) Kaplan-Meier survival curves for αCD4/8 (n = 5; median survival: 29 days), CD4KO (n = 9; median survival: 47 days), and CD8KO (n = 8; median survival: 37 days) mice implanted with αKO cells. P = 0.0017 (log-rank test, CD4KO vs CD8KO). (E) H&E-stained pancreatic sections from αCD4/8 and control mice. (F) IHC staining of pancreatic sections with antibodies against CD4 or CD8. Pancreata were collected from CD4KO or CD8KO mice at the humane endpoint. For comparison, sections of pancreata collected 10 days after implantation of B6 mice with 0.5 million αKO cells are shown. Scale bars: 100 μm. (G) Quantification of tumor-infiltrating CD4+ or CD8+ T cells from pancreatic sections.CC BY · PubMed Central
Figure 3 Adoptive T cell transfer protects SCID mice from implanted αKO tumors. (A–D) SCID mice received either no pretreatment (–T cells, n = 12) (green) or adoptive transfer of 5 million T cells harvested from B6 mice previously implanted with αKO cells (+T cells, n = 8) (orange). One day later, αKO cells (0.5 million) were implanted in the head of the pancreas of each animal. (A) Tumor growth was monitored by IVIS imaging. Representative images of 2 mice in each group are shown. (B) Quantification of luciferase signals from each mouse. Bars indicate median. *P = 0.0156 and **P = 0.0024 (Wilcoxon signed-rank test). (C) Kaplan-Meier survival curves. Median survival: –T cells, 32 days; +T cells, all were alive at day 80. P < 0.00001 (log-rank test). (D) Representative H&E-stained pancreatic sections. Pancreata were collected at the humane endpoint (–T cells) or 4 months after tumor implantation (+T cells). Scale bar: 100 μm. (E–G) 0.5 million αKO KPC cells were implanted in the head of the pancreas of SCID mice (n = 8). Four days later (t = 0), the mice were imaged by IVIS and then treated with 14.25 million or 6.38 million T cells from a convalescent B6 mouse previously implanted with αKO cells (n = 4 per group). Tumor growth was monitored by IVIS imaging. (E and F) Quantification of luciferase signals over time. (G) Mice treated with 6.38 million T cells were sacrificed at week 5 and their pancreata were collected for histology. Representative H&E and IHC images of different tumor sites from the same mouse are shown. Scale bar: 100 μm.
Figure 3 Adoptive T cell transfer protects SCID mice from implanted αKO tumors. (A–D) SCID mice received either no pretreatment (–T cells, n = 12) (green) or adoptive transfer of 5 million T cells harvested from B6 mice previously implanted with αKO cells (+T cells, n = 8) (orange). One day later, αKO cells (0.5 million) were implanted in the head of the pancreas of each animal. (A) Tumor growth was monitored by IVIS imaging. Representative images of 2 mice in each group are shown. (B) Quantification of luciferase signals from each mouse. Bars indicate median. *P = 0.0156 and **P = 0.0024 (Wilcoxon signed-rank test). (C) Kaplan-Meier survival curves. Median survival: –T cells, 32 days; +T cells, all were alive at day 80. P < 0.00001 (log-rank test). (D) Representative H&E-stained pancreatic sections. Pancreata were collected at the humane endpoint (–T cells) or 4 months after tumor implantation (+T cells). Scale bar: 100 μm. (E–G) 0.5 million αKO KPC cells were implanted in the head of the pancreas of SCID mice (n = 8). Four days later (t = 0), the mice were imaged by IVIS and then treated with 14.25 million or 6.38 million T cells from a convalescent B6 mouse previously implanted with αKO cells (n = 4 per group). Tumor growth was monitored by IVIS imaging. (E and F) Quantification of luciferase signals over time. (G) Mice treated with 6.38 million T cells were sacrificed at week 5 and their pancreata were collected for histology. Representative H&E and IHC images of different tumor sites from the same mouse are shown. Scale bar: 100 μm.CC BY · PubMed Central
Figure 4 PIK3CA regulates cell surface expression of MHC I and CD80 in KPC cells. Flow cytometric analysis of cell surface levels of (A) H-2Kb and (B) CD80 in WT and αKO cells. The left panels show representative histograms and the right graphs show the mean ± SEM of the geometric means (geo. mean) of each flow cytometry distribution. H-2Kb, n = 4; CD80, n = 3. ***P = 0.0007 (unpaired t test). (C) qRT-PCR analysis of mRNA expression of H-2Kb, B2m, and CD80 in WT and αKO cells. Gene expression changes were normalized to Hprt. Graph shows mean ± SEM (n = 6). ****P < 0.0001 (unpaired t test). (D–F) B6 mice were implanted with 0.5 million αKO/shB2m, αKO/CD80KO, or αKO/CD80KO+shB2m cells in the head of the pancreas and tumor growth was monitored by IVIS imaging. (D) Kaplan-Meier survival curves for αKO/shB2m, αKO/CD80KO, and αKO/CD80KO+shB2m mice. *A single mouse was euthanized for histology and removed from the study. Median survival: αKO/shB2m, 110.5 days; αKO/CD80KO+shB2m, 87.5 days. All αKO/CD80KO mice were alive at 115 days. P = 0.0026 (log-rank test). (E) Representative H&E and IHC images of pancreatic sections from αKO/shB2m or αKO/CD80KO+shB2m mice that died of tumor progression. Scale bar: 100 μm. (F) Representative H&E-stained pancreatic sections from a single αKO/shB2m mouse or αKO/CD80KO mice euthanized at 101 or 160 days, respectively. Scale bar: 100 μm.
Figure 4 PIK3CA regulates cell surface expression of MHC I and CD80 in KPC cells. Flow cytometric analysis of cell surface levels of (A) H-2Kb and (B) CD80 in WT and αKO cells. The left panels show representative histograms and the right graphs show the mean ± SEM of the geometric means (geo. mean) of each flow cytometry distribution. H-2Kb, n = 4; CD80, n = 3. ***P = 0.0007 (unpaired t test). (C) qRT-PCR analysis of mRNA expression of H-2Kb, B2m, and CD80 in WT and αKO cells. Gene expression changes were normalized to Hprt. Graph shows mean ± SEM (n = 6). ****P < 0.0001 (unpaired t test). (D–F) B6 mice were implanted with 0.5 million αKO/shB2m, αKO/CD80KO, or αKO/CD80KO+shB2m cells in the head of the pancreas and tumor growth was monitored by IVIS imaging. (D) Kaplan-Meier survival curves for αKO/shB2m, αKO/CD80KO, and αKO/CD80KO+shB2m mice. *A single mouse was euthanized for histology and removed from the study. Median survival: αKO/shB2m, 110.5 days; αKO/CD80KO+shB2m, 87.5 days. All αKO/CD80KO mice were alive at 115 days. P = 0.0026 (log-rank test). (E) Representative H&E and IHC images of pancreatic sections from αKO/shB2m or αKO/CD80KO+shB2m mice that died of tumor progression. Scale bar: 100 μm. (F) Representative H&E-stained pancreatic sections from a single αKO/shB2m mouse or αKO/CD80KO mice euthanized at 101 or 160 days, respectively. Scale bar: 100 μm.CC BY · PubMed Central
Figure 5 PIK3CA regulation of CD80 and MHC I is mediated by AKT signaling. (A) WT KPC cells were treated with increasing concentrations of AKT inhibitor (Akti) for 48 hours. Cell surface levels of CD80 and H-2Kb were quantified by flow cytometry. The mean ± SEM of the geometric means of each flow cytometry distribution is plotted versus inhibitor concentration (n = 3 for each inhibitor concentration). †P = 0.0031 (H-2Kb) and ‡P = 0.0018 (CD80) for DMSO versus 20 μM Akti (2-tailed paired t test). (B) Four parental KPC cell lines were treated with 10 μM Akti for 48 hours. Cell surface levels of H-2Kb (left) and CD80 (right) were determined by flow cytometry (n = 4). The graphs show fold change (mean ± SEM) over DMSO. *P < 0.05, **P < 0.005, ***P < 0.0005. (C) Human pancreatic cell lines were treated with 10 μM Akti for 48 hours. Cell surface levels of HLA-ABC (left) and CD80 (right) were determined by flow cytometry (n = 3). The graph shows fold change (mean ± SEM) over DMSO. *P < 0.05, **P < 0.005. (D–H) αKO-Cont or αKO-caAkt cells (0.5 million) were implanted in the head of the pancreas of B6 mice. (D) Representative IVIS images showing tumor size on days 1 and 21. (E) Quantification of luciferase signals in each mouse. αKO-Cont, n = 3 and αKO-caAkt, n = 6. (F) Kaplan-Meier survival curves. Median survival: αKO-caAkt, 31 days. All αKO-Cont mice were alive at 71 days. P = 0.011 (log-rank test). (G) Representative H&E-stained pancreatic sections from mice implanted with αKO-Cont cells (euthanized at 71 days) or αKO-caAkt cells (postmortem). (H) Representative IHC images of pancreatic sections from mice implanted with αKO-caAkt cells (postmortem). For G and H, n = 3. Scale bar: 100 μm.
Figure 5 PIK3CA regulation of CD80 and MHC I is mediated by AKT signaling. (A) WT KPC cells were treated with increasing concentrations of AKT inhibitor (Akti) for 48 hours. Cell surface levels of CD80 and H-2Kb were quantified by flow cytometry. The mean ± SEM of the geometric means of each flow cytometry distribution is plotted versus inhibitor concentration (n = 3 for each inhibitor concentration). †P = 0.0031 (H-2Kb) and ‡P = 0.0018 (CD80) for DMSO versus 20 μM Akti (2-tailed paired t test). (B) Four parental KPC cell lines were treated with 10 μM Akti for 48 hours. Cell surface levels of H-2Kb (left) and CD80 (right) were determined by flow cytometry (n = 4). The graphs show fold change (mean ± SEM) over DMSO. *P < 0.05, **P < 0.005, ***P < 0.0005. (C) Human pancreatic cell lines were treated with 10 μM Akti for 48 hours. Cell surface levels of HLA-ABC (left) and CD80 (right) were determined by flow cytometry (n = 3). The graph shows fold change (mean ± SEM) over DMSO. *P < 0.05, **P < 0.005. (D–H) αKO-Cont or αKO-caAkt cells (0.5 million) were implanted in the head of the pancreas of B6 mice. (D) Representative IVIS images showing tumor size on days 1 and 21. (E) Quantification of luciferase signals in each mouse. αKO-Cont, n = 3 and αKO-caAkt, n = 6. (F) Kaplan-Meier survival curves. Median survival: αKO-caAkt, 31 days. All αKO-Cont mice were alive at 71 days. P = 0.011 (log-rank test). (G) Representative H&E-stained pancreatic sections from mice implanted with αKO-Cont cells (euthanized at 71 days) or αKO-caAkt cells (postmortem). (H) Representative IHC images of pancreatic sections from mice implanted with αKO-caAkt cells (postmortem). For G and H, n = 3. Scale bar: 100 μm.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 85

Metadata

Authors
Sivaram, N., McLaughlin, P. A., Han, H. V., Petrenko, O., Jiang, Y.-P., Ballou, L. M., Pham, K., Liu, C., van der Velden, A. W. M., & Lin, R. Z.
Affiliations
  • Stony Brook University (US)
  • Rutgers, The State University of New Jersey (US)
  • Northport VA Medical Center (US)
Corresponding author
Lin, Richard Z.
Venue
Journal of Clinical Investigation
Published
2019-07-15
Volume
129
Issue
8
Pages
3264-3276
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2945115405
Cited by
78
References
71
Citations by year
2026: 4 · 2025: 11 · 2024: 11 · 2023: 18 · 2022: 10 · 2021: 15 · 2020: 7 · 2019: 2
FWCI
3.55
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Veterans Affairs (BX004083)
  • National Cancer Institute (CA194836)
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK108989)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
PIK3CA, Akt signaling, pancreatic cancer, tumor immunogenicity, tumor-infiltrating T cells, KRAS G12D, MHC class I expression, CD80, T cell surveillance, adoptive T cell therapy, cancer immunotherapy, tumor immunosuppression
MeSH terms
Animals, Humans, Neoplasms, Experimental, Pancreatic Neoplasms, T-Lymphocytes, Histocompatibility Antigens Class I, Signal Transduction, Lymphocytes, Tumor-Infiltrating, Mice, SCID, B7-1 Antigen, Mice, Knockout, Adoptive Transfer, Xenograft Model Antitumor Assays, Cell Line, Tumor, Proto-Oncogene Proteins c-akt, Mice, Class I Phosphatidylinositol 3-Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.